University Hospitals will lead a clinical trial of an investigational drug manufactured by a Cleveland company to assess whether it helps prevent airborne transmission of coronavirus and whether it reduces the symptoms of health care providers who have tested positive for COVID-19.
The Cleveland Foundation has authorized $1 million in emergency funding to support a significant portion of the clinical trial from previously restricted health-related research grant dollars at the foundation, according to a news release.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutre.
Originally published April 2, 2020.